Navigation Links
MicroRNA-218 targets medulloblastoma, most aggressive childhood brain cancer
Date:12/13/2012

Between the blueprint of the genome and the products of its expression lie microRNAs, which can boost or lower the rate at which genes become stuff. In fact, many cancers use microRNA to magnify the expression of faulty genes or shrink the expression of helpful genes that would otherwise suppress tumors. A University of Colorado Cancer Center study published in the December issue of the Journal of Biological Chemistry shows that in medulloblastoma, a malignant brain tumor of children, microRNA-218 is especially low. The article also shows that adding microRNA-218 to neural stem cells engineered to develop medulloblastoma decreases the development of the cancer.

"For the past five years, we've been looking at microRNAs in medulloblastoma, asking how they are normally expressed and how this expression differs in the disease. One of the microRNA's most different in the medulloblastoma is microRNA-218," says Rajeev Vibhakar, MD, PhD, MPH, investigator at the CU Cancer Center, assistant professor of pediatrics at the CU School of Medicine, and the paper's senior author.

When Vibhakar and colleagues inquired into the effects of lower microRNA-218 levels, they found its involvement in pathways that signal the metabolism, growth, migration and invasion of tumor tissues. MicroRNA-218 is a tumor suppressor low miRNA-218 equals low function in a range of tumor suppressor genes, equals high tumor growth.

In fact, the group found 618 genes whose expression was manipulated by microRNA-218.

"One of these genes was CDK6," Vibhakar says. Finding a gene target is especially important because whereas it's difficult to drug microRNA it's fairly simple to drug genes. As it turned out, Pfizer already had a drug that targets CDK6 and in a follow-up study published in the Journal of NeuroOncology, when Vibhakar and colleagues tested the drug in medulloblastoma cells, they found reduced cancer cell survival.

"Especially important is the fact that the drug led to increased radiation sensitivity in cancer cells," Vibhakar says. "Because medulloblastoma is most common in children and because high doses of radiation in children can have adverse long-term side effects, the prospect of a drug that could reduce the intensity of the required radiation is very appealing."

For similar reasons, despite the finding of a druggable target, the group plans to continue its work with microRNA-218. Specifically, the microRNA seems involved in cancer cell migration and invasion because medulloblastoma is aggressively metastatic along the spinal cord, any advances in stopping the march of the disease from the brain could lead to major patient gains, especially in pediatric patients.

"Also interesting is the fact that studies of microRNA are leading us to genes implicated in cancer that we may not have discovered otherwise," Vibhakar says. In many ways this is the reverse of the traditional workflow in discovering a druggable target. Usually, a researcher would explore for genetic abnormalities and then if needed search inside the gene's signaling chain for a way to turn it on or off. With microRNA, researchers look first for abnormalities in the signaling chain, and then work higher in the system to discover the associated genetic abnormalities and their functions.

Because many of the pathways affected by microRNA-218 are common across many types of cancer, the findings may have implications far beyond medulloblastoma.


'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert

Related biology news :

1. Discovery of pathway leading to depression reveals new drug targets
2. Discovery of molecular pathway of Alzheimers disease reveals new drug targets
3. Naïve fish: Easy targets for spear fishers
4. New potential targets discovered for treating squamous cell lung cancers
5. Scientists use worms to unearth cancer drug targets
6. Wayne State University researchers program targets safer river fishing, anglers health
7. Blocking DNA: HDAC inhibitor targets triple negative breast cancer
8. Its a trap! New laboratory technique captures microRNA targets
9. Unique adaptations to a symbiotic lifestyle reveal novel targets for aphid insecticides
10. Scripps Research Institute scientists find promising vaccine targets on hepatitis C virus
11. Crestor Delivers Latest LDL-C Targets in High-Risk Patients at Lower Doses than Other Statins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2017)... --  Bridge Patient Portal , an enterprise patient ... Systems , an electronic medical record solutions developer ... a partnership to build an interface between the ... products, including Centricity Practice Solution (CPS), Centricity Business ... integrations will allow healthcare delivery networks using GE ...
(Date:4/19/2017)... April 19, 2017 The global ... landscape is marked by the presence of several large ... held by five major players - 3M Cogent, NEC ... accounted for nearly 61% of the global military biometric ... in the global military biometrics market boast global presence, ...
(Date:4/13/2017)... 13, 2017 UBM,s Advanced Design and Manufacturing ... feature emerging and evolving technology through its 3D Printing ... run alongside the expo portion of the event and ... demonstrations focused on trending topics within 3D printing and ... manufacturing event will take place June 13-15, 2017 at the ...
Breaking Biology News(10 mins):
(Date:6/23/2017)... ... June 23, 2017 , ... ... for all six of their healthcare job boards. As the largest network ... occupational therapists, and biotechnicians, DocCafe.com and the MedJobCafe.com Health Network work to ...
(Date:6/22/2017)... , ... June 22, 2017 , ... ... over the allergy specialists DST Diagnostische Systeme & Technologien GmbH, thereby expanding its ... someone who suffers from hay fever, urticaria, asthma, atopic eczema or a food ...
(Date:6/22/2017)... Frederick, MD (PRWEB) , ... June 22, 2017 ... ... software solutions provider, announced the release of Limfinity® version 6.5, a content-packed update ... Limfinity® framework continue to gain a larger and more diverse base of customers ...
(Date:6/20/2017)... June 20, 2017  Kibow Biotech Inc., a pioneer ... the issuance of a new patent covering a unique ... the U.S. Patent and Trademark Office on May 23 ... the Buzz of Bio award in 2014 in ... developing non-drug approaches to chronic disease. Renadylâ„¢, the first ...
Breaking Biology Technology: